MRC1 and neoplasm: Positive MSI patients or with the altering of MMR genes on IHC, patients whose MSI/ IHC tumor testing is unavailable, but in whom there is a strong clinical suspicion (Bethesda Criteria), as well as patients who meet the Amsterdam II criteria in the absence of tumor testing, need the testing of germinal lines in order to determine MMR/ EPCAM mutations.